Nephros Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Nephros de 107% y 13.9% respectivamente, mientras que el BPA crecerá en un 108% al año.

Información clave

107.0%

Tasa de crecimiento de los beneficios

108.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Consumer Durables	8.0%
Tasa de crecimiento de los ingresos	13.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	08 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

After Leaping 40% Nephros, Inc. (NASDAQ:NEPH) Shares Are Not Flying Under The Radar

Dec 18

At US$3.18, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?

Dec 14

Nephros partners with Donastar and Tractor Beverage to supply and service nationwide fast-casual restaurant operation

Sep 28

US$5.13: That's What Analysts Think Nephros, Inc. (NASDAQ:NEPH) Is Worth After Its Latest Results

Aug 13

Market Sentiment Around Loss-Making Nephros, Inc. (NASDAQ:NEPH)

Mar 25

At US$8.37, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?

Mar 04

Announcing: Nephros (NASDAQ:NEPH) Stock Increased An Energizing 131% In The Last Five Years

Jan 28

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:NEPH - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	19	0	N/A	N/A	1
12/31/2024	17	-1	N/A	N/A	2
12/31/2023	14	-2	1	1	N/A
9/30/2023	14	-2	1	1	N/A
6/30/2023	12	-3	0	0	N/A
3/31/2023	12	-3	-1	-1	N/A
12/31/2022	10	-5	-3	-3	N/A
9/30/2022	10	-5	-4	-3	N/A
6/30/2022	10	-4	-4	-4	N/A
3/31/2022	10	-4	-3	-3	N/A
12/31/2021	10	-3	-2	-1	N/A
9/30/2021	10	-3	-3	-3	N/A
6/30/2021	9	-4	-4	-4	N/A
3/31/2021	9	-4	-5	-5	N/A
12/31/2020	9	-5	-7	-7	N/A
9/30/2020	9	-4	-5	-5	N/A
6/30/2020	10	-4	-4	-4	N/A
3/31/2020	11	-3	-3	-3	N/A
12/31/2019	10	-3	-2	-2	N/A
9/30/2019	9	-4	-3	-3	N/A
6/30/2019	7	-4	-4	-4	N/A
3/31/2019	6	-3	-4	-4	N/A
12/31/2018	6	-3	-4	-4	N/A
9/30/2018	5	-1	-1	-1	N/A
6/30/2018	5	-1	-1	-1	N/A
3/31/2018	4	-2	0	0	N/A
12/31/2017	4	-1	0	0	N/A
9/30/2017	3	-3	N/A	-2	N/A
6/30/2017	3	-3	N/A	-2	N/A
3/31/2017	2	-3	N/A	-2	N/A
12/31/2016	2	-3	N/A	-2	N/A
9/30/2016	2	-3	N/A	-3	N/A
6/30/2016	2	-3	N/A	-3	N/A
3/31/2016	2	-4	N/A	-3	N/A
12/31/2015	2	-3	N/A	-4	N/A
9/30/2015	2	-3	N/A	-3	N/A
6/30/2015	2	0	N/A	-3	N/A
3/31/2015	2	-4	N/A	-3	N/A
12/31/2014	2	-7	N/A	-2	N/A
9/30/2014	2	-2	N/A	-3	N/A
6/30/2014	2	-6	N/A	-2	N/A
3/31/2014	2	-1	N/A	-3	N/A
12/31/2013	2	1	N/A	-4	N/A
9/30/2013	2	-4	N/A	-3	N/A
6/30/2013	2	-4	N/A	-4	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que NEPH sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que NEPH sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que NEPH sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (13.9% al año) de NEPH crezcan más rápidamente que los del mercado US (8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 13.9% al año) de NEPH crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de NEPH se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Nephros Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates upgraded to US$0.12 loss

Consensus estimates of losses per share improve by 30%

Forecast to breakeven in 2025

No longer forecast to breakeven

Forecast to breakeven in 2024

Consensus EPS estimates fall by 37%

Recent updates

Nephros, Inc., Annual General Meeting, May 23, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

Nephros, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Now 21% undervalued

Now 25% undervalued

After Leaping 40% Nephros, Inc. (NASDAQ:NEPH) Shares Are Not Flying Under The Radar

At US$3.18, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?

Consensus EPS estimates upgraded to US$0.12 loss

Consensus estimates of losses per share improve by 30%

Forecast to breakeven in 2025

Nephros, Inc., Hires Judy Krandel as Chief Financial Officer

Nephros, Inc., Hires Judy Krandel as Chief Financial Officer

Nephros, Inc. to Report Q3, 2023 Results on Nov 08, 2023

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Nephros, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New major risk - Share price stability

No longer forecast to breakeven

First quarter 2023 earnings: EPS misses analyst expectations

Nephros, Inc. Announces CEO Changes

Forecast to breakeven in 2024

Consensus EPS estimates fall by 37%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased by 27% to US$3.00

Less than half of directors are independent

Nephros, Inc. Announces Board Changes

Nephros, Inc. to Report Q4, 2022 Results on Mar 08, 2023

Nephros, Inc. announced delayed 10-Q filing

Price target decreased to US$3.63

Consensus EPS estimates fall by 23%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Nephros, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Nephros partners with Donastar and Tractor Beverage to supply and service nationwide fast-casual restaurant operation

Nephros Appoints Joe Harris to Its Board of Directors

Wes Lobo, Chief Commercial Officer of Nephros, Inc. Resigns, to Be Effective No Later Than September 30, 2022

US$5.13: That's What Analysts Think Nephros, Inc. (NASDAQ:NEPH) Is Worth After Its Latest Results

Second quarter 2022 earnings: EPS exceeds analyst expectations

Nephros, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Nephros Receives FDA 510(k) Clearance for HDF Assist Module

Consensus revenue estimates fall by 17%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$9.33

Nephros, Inc., Annual General Meeting, May 19, 2022

Full year 2021 earnings: EPS misses analyst expectations

Nephros, Inc. Reaffirms Revenue Guidance for the Fiscal Year 2022

Price target decreased to US$12.33

Nephros, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021 and for the Year 2022

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.12 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.19 loss in 2Q 2020)

Forecast to breakeven in 2023

No longer forecast to breakeven

Consensus revenue estimates fall to US$10.9m

First quarter 2021 earnings released: US$0.06 loss per share (vs US$0.14 loss in 1Q 2020)

Nephros, Inc. Provides Revenue Guidance for the Quarter Ended March 31, 2021

Market Sentiment Around Loss-Making Nephros, Inc. (NASDAQ:NEPH)

Analysts lower revenue estimates to US$11.5m

At US$8.37, Is It Time To Put Nephros, Inc. (NASDAQ:NEPH) On Your Watch List?

Full year 2020 earnings released: US$0.53 loss per share (vs US$0.45 loss in FY 2019)

Revenue beats expectations, earnings disappoint

Nephros, Inc. to Report Q4, 2020 Results on Mar 01, 2021

Nephros, Inc. Hires Wes Lobo as Chief Marketing Officer

New 90-day high: US$8.93

Nephros, Inc. Announces Management Changes

Chief Financial Officer has left the company

Announcing: Nephros (NASDAQ:NEPH) Stock Increased An Energizing 131% In The Last Five Years

Nephros sees Q4 revenue in-line with estimates,

New 90-day high: US$7.39